Immunosuppressive therapies in the management of acquired immune-mediated marrow failures

Current Opinion in Hematology

Volumn 19, Issue 1, 2012, Pages 3-13

  Risitano, Antonio M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Antithymocyte globulin; Aplastic anemia; Bone marrow failure; Cyclosporine A; Immunosuppression

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; THYMOCYTE ANTIBODY; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

APLASTIC ANEMIA; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CLONAL EVOLUTION; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; HEALTH CARE QUALITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOCYTE DEPLETION; LYMPHOCYTOPENIA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NATIONAL HEALTH ORGANIZATION; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCYTOPENIA; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; SINGLE DRUG DOSE; WHOLE BODY RADIATION; ANIMAL; HORSE; METHODOLOGY; RABBIT;

ANEMIA, APLASTIC; ANIMALS; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; HEMOGLOBINURIA, PAROXYSMAL; HORSES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; RABBITS;

EID: 84856430914     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32834da9a4     Document Type: Review

References (79)

1. Young NS. Acquired aplastic anemia. In: Young NS, editor. Bone marrow failure syndromes. Philadelphia: WB Saunders; 2000. pp. 1-46.
2. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336:1365-1372.
3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006; 108:2509-2519.
4. Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004; 364:355-364.
5. Calado RT. Telomeres and marrow failure. Hematol Am Soc Hematol Educ Program 2009; 2009:338-343.
6. Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009; 94:449-451.
7. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147:43-70.
8. Risitano AM. Immunosuppressive therapies in the management of immunemediated marrow failures in adults: where we stand and where we are going. Br J Haematol 2011; 152:127-140.
9. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 1993; 308:113-118.
10. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med 1991; 324:1297-1304.
11. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. German aplastic anemia study group. Antithymocyte globulin with or without cyclosporin A: 11- year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003; 101:1236-1242.
12. Rosenfeld SJ, Kimball J, Vining D, Young NS. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995; 85:3058-3065.
13. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. J Am Med Assoc 2003; 289:1130-1135.
14. Locasciulli A, Oneto R, Bacigalupo A, et al. Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplant Group. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2007; 92:11-18.
15. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 2000; 95:1931-1934.
16. Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007; 110:1756-1761.
17. Scheinberg P, Wu CO, Nunez O, Young NS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009; 144:206-216.
18. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica 2009; 94:348-354.
19. Tichelli A, Schrezenmeier H, Socie G, et al. A randomized controlled study in newly-diagnosed severe aplastic anemia patients receiving antithymocyte globulin, ciclosporin, with or without G-CSF. Blood 2011; 117:4434-4441.
20. Scheinberg P, Nunez O, Wu C, Young NS. Treatment of severe aplastic anaemia with combined immunosuppression: antithymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol 2006; 133:606-611.
21. Di Bona E, Rodeghiero F, Bruno B, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 1999; 107:330-334.
22. Scheinberg P, Nunez O, Young NS. Re-treatment with rabbit antithymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol 2006; 133:622-627.
23. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67:1011-1018; Erratum, Transplantation 1999;67:1386..
24. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66:29-37. 25
25. Scheinberg P, Nunez O, Weinstein BP, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365:430-438
26. Marsh J, Socie G, Tichelli A, et al. On behalf of the EBMT Severe Aplastic Anaemia (SAA) Working Party. Prospective phase II pilot study of rabbit antithymocyte globulin with ciclosporin for patients with acquired aplastic anaemia and matched pair analysis with patients treated with horse ATG and ciclosporin. Bone Marrow Transplant 2011; 46 (S1):208
27. Kadia T, Ravandi F, Garcia-Manero G, et al. Updated results of combination cytokine immunotherpay in the treatment of aplastic anaemia and myelodysplastic syndroems (MDS). Blood 2010; 116 s1:2920(a).
28. Afable MG, Shaik M, Sugimoto Y, et al. Efficacy of rabbit antithymocyte globulin in severe aplastic anemia. Haematologica 2011; 96:1269-1275
29. Atta EA, Dias SP, Marra VLN, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first line treatment for patients with severe aplastic anemia: a single centre retrospective study. Ann Hematol 2010; 89:851-859
30. Halkes CJM, Brand A, von dem Borne PA, et al. Increasing the dose of rabbit- ATG does not lead to a higher response rate in the first-line treatment of severe aplastic anaemia. Bone Marrow Transplant 2011; 46:S90-S389. doi:10.1038/bmt.2011.48.
31. Saracco P, Lorenzati A, Oneto R, et al. On behalf of the AIEOP Bone Marrow Failure Study Group. Italian registry of pediatric acquired aplastic anaemia: a retrospective study. Bone Marrow Transplant 2011; 46:S90-S389. doi:10.1038/bmt.2011.48.
32. Vallejo C, Montesinos P, Rosell A, et al. Comparison between lymphoglobuline-and thymoglobuline-based immunosuppressive therapy as first-line treatment for patients with aplastic anemia. Blood 2009; 114:3194a.
33. European Blood and Marrow Transplant Group, Severe Aplastic Anemia Working Party. Rabbit ATG for aplastic anaemia treatment: a backward step? Lancet 2011; doi: 10.1016/S0140-6736(11)60817-9. [Epub ahead of print]
34. Serefhanoglu S, Buyukasik Y, Purnak T, et al. A comparison of Jurkat cellreactive anti-T lymphocyte globulin and fetal antithymocyte globulin preparations in the treatment of aplastic anemia. Med Princ Pract 2011; 20:341-344
35. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): A prospective comparison of four different regimens. Experiment Hematol 2006; 34:826-831.
36. Bing H, Siyi Y, Wei Z, et al. The use of antihuman T lymphocyte porcine immunoglobulin and cyclosporine a to treat patients with acquired severe aplastic anemia. Acta Haematol 2010; 124:245-250
37. Dufour C, Giacchino R, Ghezzi P, et al. Etanercept as a salvage treatment for refractory aplastic anemia. Pediatr Blood Cancer 2009; 52:522-525.
38. Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood 1996; 87:491-494.
39. Tisdale JF, Dunn DE, Geller N, et al. High-dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet 2000; 356:1554-1559.
40. Tisdale JF, Maciejewski JP, Nunez O, et al. Late complications following treatment for severe aplastic anemia (SAA) with high-dose cyclophosphamide (Cy): follow-up of a randomized trial. Blood 2002; 100:4668-4670.
41. Brodsky RA, Chen AR, Dorr D, et al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood 2010; 115:2136-2141
42. Risitano AM, Selleri C, Serio B, et al. Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148:791-796
43. Kim H, Min YJ, Baek JH, et al. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 2009; 33:222-231.
44. Risitano AM, Selleri C, Serio B, et al. Alemtuzumab for aplastic anemia and related immune-mediated bone marrow failures: long-term follow up of a pilot study. Haematologica 2011; 96 (s2):105a.
45. Gómez-Almaguer D, Jaime-Pérez JC, Garza-Rodríguez V, et al. Subcutaneous alemtuzumab plus cyclosporine for the treatment of aplastic anemia. Ann Hematol 2010; 89:299-303
46. Scheinberg P, Nunez O, Weinstein B, et al. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. Blood 2011. [Epub ahead of print]
47. Scheinberg P, Fischer SH, Li L, et al. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood 2007; 109:3219-3224.
48. LaCorcia G, Swistak M, Lawendowski C, et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosoppressive capabilities beyond cell depletion. Transplantation 2009; 87:966-974.
49. Kawano Y, Nissen C, Gratwohl A, et al. Cytotoxic and stimulatory effects of antilymphocyte globulin (ALG) on hematopoiesis. Blut 1990; 60:297-300.
50. Barbano GC, Schenone A, Roncella S, et al. Antilymphocyte globulin stimulates normal human T cells to proliferate and to release lymphokines in vitro: a study at the clonal level. Blood 1988; 72:956-963.
51. Flynn J, Cox CV, Rizzo S, et al. Direct binding of antithymoctye globulin to haemopoietic progenitor cells in aplastic anaemia. Br J Haematol 2003; 122:289-297.
52. Solomou EE, Rezvani K, Mielke S, et al. Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood 2007; 110:1603-1606.
53. de Latour RP, Visconte V, Takaku T, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood 2010; 116:4175-4184.
54. Zeng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25high FOXP3+ regulatory T cells in vitro. Blood 2008; 111:3675-3683.
55. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for antithymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006; 17:2844-2853.
56. Smith AG, O'Reilly RJ, Hansen JA, Martin PJ. Specific antibody-blocking activities in antilymphocyte globulin as correlates of efficacy for the treatment of aplastic anemia. Blood 1985; 66:721-723.
57. Raefsky EL, Gascon P, Gratwohl A, et al. Biological and immunological characterization of ATG and ALG. Blood 1986; 68:712-719.
58. Mueller TF. Thymoglobulin: an immunologic overview. Curr Opin Organ Transplant 2003; 8:305-312.
59. Tsuge I, Kojima S. Comparison of antibody specificities of four antithymocyte/ antilymphocyte globulin products. Curr Ther Res 1995; 56:671-677.
60. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59:194-200.
61. Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica 2000; 85:133-138.
62. Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk Res 2003; 27:783-788.
63. Jonásova A, Neuwirtová R, Cermák J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998; 100:304-309.
64. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100:1570-1574.
65. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007; 21:1436-1441.
66. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26:2505-2511.
67. Steensma DP, Dispenzieri A, Moore SB, et al. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003; 101:2156-2158.
68. Passweg JR, Giagounidis AA, SimcockM, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care: SAKK 33/99. J Clin Oncol 2011; 29:303-309
69. Sloand EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate- 1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010; 28:5166-5173
70. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol 2008; 142:505-514.
71. Sawada K, Hirokawa M, Fujishima N, et al. PRCA Collaborative Study Group. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 2007; 92:1021-1028.
72. Marsh JC, Gordon-Smith EC. The role of antilymphocyte globulin in the treatment of chronic acquired bone marrow failure. Blood Rev 1988; 2:141-148.
73. Sloand EM, Olnes MJ, Weinstein B, et al. Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. Haematologica 2010; 95:382-387.
74. The complete treatment algorithm for SAA (prepared by EBMT SAAWP), 12 February 2011. http://www.ebmt.org/5WorkingParties/AAWP/wparties-aa3.html.
75. Bacigalupo A, Oneto R, Bruno B, et al. Current results of bone marrow transplantation in patients with acquired severe aplastic anemia. Report of the European Group for Blood and Marrow transplantation. On behalf of the Working Party on Severe Aplastic Anemia of the European Group for Blood and Marrow Transplantation. Acta Haematologica 2000; 103:19-25.
76. Passweg JR, Marsh JC. Aplastic anemia: first-line treatment by immunosuppression and sibling marrow transplantation. Hematol Am Soc Hematol Educ Program 2010; 2010:36-42.
77. Maury S, Bacigalupo A, Anderlini P, et al. Severe Aplastic Anemia Working Party, European Group for Blood and Marrow Transplantation (EBMTSAAWP). Improved outcome of patients older than 30 years receiving HLAidentical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica 2009; 94:1312-1315.
78. Bacigalupo A, SociéG, Lanino E, et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica 2010; 95:976-982.
79. Passweg JR, Tichelli A. Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica 2009; 94:310-312.